<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>An Interpretable AI Tool for SAVR vs TAVR in Low to Intermediate Risk Patients with Severe Aortic Stenosis - Health AI Hub</title>
    <meta name="description" content="This paper introduces an interpretable AI-driven prescriptive framework to optimize treatment selection between surgical (SAVR) and transcatheter (TAVR) aortic ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>An Interpretable AI Tool for SAVR vs TAVR in Low to Intermediate Risk Patients with Severe Aortic Stenosis</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.10308v1" target="_blank">2512.10308v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-11
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Vasiliki Stoumpou, Maciej Tysarowski, Talhat Azemi, Jawad Haider, Howard L. Haronian, Robert C. Hagberg, Dimitris Bertsimas
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.10308v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.10308v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">This paper introduces an interpretable AI-driven prescriptive framework to optimize treatment selection between surgical (SAVR) and transcatheter (TAVR) aortic valve replacement for low to intermediate risk patients with severe aortic stenosis. By integrating prognostic matching, counterfactual outcome modeling, and an Optimal Policy Tree, the tool recommends the treatment minimizing expected 5-year mortality. The framework demonstrated significant estimated reductions in 5-year mortality (20.3% internally, 13.8% externally) compared to real-life prescriptions, while maintaining clinical interpretability.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is highly relevant for cardiologists and cardiac surgeons as it provides a data-driven, interpretable tool to guide optimal treatment selection for severe aortic stenosis patients. By directly optimizing for long-term survival and offering patient-specific recommendations, it can standardize care, reduce mortality, and minimize variability driven by institutional or physician preferences.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>An interpretable AI tool using machine learning (prognostic matching, counterfactual outcome modeling, and Optimal Policy Trees) to generate personalized treatment recommendations (SAVR vs. TAVR) for patients with severe aortic stenosis, with the goal of minimizing 5-year mortality. It functions as a clinical decision support system, aiding physicians in making evidence-based choices for individual patients.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the clinical challenge of variable and non-individualized treatment selection for SAVR vs TAVR in low-to-intermediate risk severe aortic stenosis patients.</li>
                    
                    <li>Proposes an interpretable prescriptive framework consisting of prognostic matching, counterfactual outcome modeling, and an Optimal Policy Tree (OPT) to provide individualized treatment recommendations.</li>
                    
                    <li>The framework's primary goal is to minimize estimated 5-year mortality by prescribing the optimal treatment (SAVR or TAVR) for distinct patient subgroups.</li>
                    
                    <li>Utilizes real-world data from two hospitals (Hartford and St. Vincent's) to emulate randomization, estimate counterfactual mortality, and train the policy model.</li>
                    
                    <li>Counterfactual evaluation showed an estimated 20.3% reduction in 5-year mortality in the internal Hartford cohort and 13.8% in the external St. Vincent's cohort, if the OPT's prescriptions were applied.</li>
                    
                    <li>Demonstrates promising generalizability to an unseen external dataset and ensures that the learned decision boundaries are clinically coherent and align with real-world outcomes.</li>
                    
                    <li>Presents the first known transparent and data-driven framework for SAVR/TAVR decision-making that improves estimated long-term outcomes in both internal and external cohorts, promoting precision medicine.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>The methodology centers on an 'interpretable prescriptive framework'. It involves: 1) **Prognostic Matching and Sample Weighting** to emulate randomization and address confounding in observational data, creating balanced cohorts for counterfactual analysis. 2) **Counterfactual Outcome Modeling** to estimate each patient's expected 5-year mortality under both SAVR and TAVR treatments. 3) An **Optimal Policy Tree (OPT)**, a machine learning model, trained on these counterfactual predictions to partition patients into clinically coherent subgroups and prescribe the treatment (SAVR or TAVR) associated with the lowest estimated 5-year mortality for each subgroup.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>The primary findings indicate a substantial estimated improvement in patient outcomes if the AI tool's prescriptions are followed: a 20.3% reduction in 5-year mortality for the internal Hartford cohort and a 13.8% reduction for the external St. Vincent's cohort. These results demonstrate strong generalizability. Furthermore, the decision boundaries derived by the Optimal Policy Tree were found to be clinically coherent, aligning with existing medical knowledge and real-world outcomes.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This tool has the potential to significantly impact clinical practice by providing objective, individualized, and transparent treatment recommendations for SAVR vs TAVR. It could lead to a more systematic and evidence-based approach to decision-making, reducing unwarranted variability, improving long-term patient survival, and fostering trust through its interpretability. It supports the advancement of precision medicine in structural heart disease by optimizing treatment choices for each patient.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly detailed in the abstract. However, inherent limitations in such models often include reliance on specific institutional data (even with external validation, broader applicability might require more diverse datasets) and the challenges of accurately estimating counterfactuals in complex biological systems.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly detailed in the abstract. Implicitly, future work could involve validating the framework with larger, multi-center, and prospective datasets, exploring its effectiveness across different risk strata, and integrating it into electronic health record systems for real-time clinical decision support.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Cardiology</span>
                    
                    <span class="tag">Cardiovascular Surgery</span>
                    
                    <span class="tag">Interventional Cardiology</span>
                    
                    <span class="tag">Structural Heart Disease</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">interpretable AI</span>
                    
                    <span class="tag tag-keyword">SAVR</span>
                    
                    <span class="tag tag-keyword">TAVR</span>
                    
                    <span class="tag tag-keyword">aortic stenosis</span>
                    
                    <span class="tag tag-keyword">prescriptive analytics</span>
                    
                    <span class="tag tag-keyword">counterfactual modeling</span>
                    
                    <span class="tag tag-keyword">mortality reduction</span>
                    
                    <span class="tag tag-keyword">precision medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Background. Treatment selection for low to intermediate risk patients with severe aortic stenosis between surgical (SAVR) and transcatheter (TAVR) aortic valve replacement remains variable in clinical practice, driven by patient heterogeneity and institutional preferences. While existing models predict postprocedural risk, there is a lack of interpretable, individualized treatment recommendations that directly optimize long-term outcomes.
  Methods. We introduce an interpretable prescriptive framework that integrates prognostic matching, counterfactual outcome modeling, and an Optimal Policy Tree (OPT) to recommend the treatment minimizing expected 5-year mortality. Using data from Hartford Hospital and St. Vincent's Hospital, we emulate randomization via prognostic matching and sample weighting and estimate counterfactual mortality under both SAVR and TAVR. The policy model, trained on these counterfactual predictions, partitions patients into clinically coherent subgroups and prescribes the treatment associated with lower estimated risk.
  Findings. If the OPT prescriptions are applied, counterfactual evaluation showed an estimated reduction in 5-year mortality of 20.3\% in Hartford and 13.8\% in St. Vincent's relative to real-life prescriptions, showing promising generalizability to unseen data from a different institution. The learned decision boundaries aligned with real-world outcomes and clinical observations.
  Interpretation. Our interpretable prescriptive framework is, to the best of our knowledge, the first to provide transparent, data-driven recommendations for TAVR versus SAVR that improve estimated long-term outcomes both in an internal and external cohort, while remaining clinically grounded and contributing toward a more systematic and evidence-based approach to precision medicine in structural heart disease.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>